Skip to main content
SpringerLink
Log in

Mucormycosis and Entomophthoramycosis (Zygomycosis)

  • Chapter
  • First Online:
Essentials of Clinical Mycology

Abstract

Previously the term zygomycosis was used to refer to infections caused by fungi belonging to the phylum Zygomycota, class Zygomycetes, orders Mucorales and Entomophthorales. However, a more recent classification based on molecular phylogenetic studies of rRNA, tef1, and rpb1, has abolished the class Zygomycetes and instead distributes fungi previously in the phylum Zygomycota into the phylum Glomeromycota and four subphyla, ­including Mucoromycotina, Kickxellomycotina, Zoopagomycotina, and Entomophthoromycotina (Table 1) [1]. Therefore, the term zygomycosis, which has been used by clinicians and mycologists for decades, is no longer relevant to fungal taxonomy. Both terms, mucormycosis and zygomycosis, are used throughout this book, reflecting the recent changes in nomenclature and the slower evolution of clinical parlance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hibbett DS, Binder M, Bischoff JF, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res. 2007;111:509–47.

    PubMed  Google Scholar 

  2. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13:236–301.

    CAS  PubMed  Google Scholar 

  3. Sugar AM. Agents of Mucormycosis and Related Species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier; 2005. 2979.

    Google Scholar 

  4. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–69.

    CAS  PubMed  Google Scholar 

  5. Kwon-Chung KJ, Bennett JE. Mucormycosis. In: Medical mycology. Philadelphia: Lea & Febiger; 1992. p. 524–59.

    Google Scholar 

  6. Cohen-Abbo A, Bozeman PM, Patrick CC. Cunninghamella infections: review and report of two cases of Cunninghamella pneumonia in immunocompromised children. Clin Infect Dis. 1993;17:173–7.

    CAS  PubMed  Google Scholar 

  7. Kontoyianis DP, Vartivarian S, Anaissie EJ, Samonis G, Bodey GP, Rinaldi M. Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. Clin Infect Dis. 1994;18:925–8.

    CAS  PubMed  Google Scholar 

  8. Kwon-Chung KJ, Young RC, Orlando M. Pulmonary mucormycosis caused by Cunninghamella elegans in a patient with chronic myelogenous leukemia. Am J Clin Pathol. 1975;64:544–8.

    CAS  PubMed  Google Scholar 

  9. Motohashi K, Ito S, Hagihara M, Maruta A, Ishigatsubo Y, Kanamori H. Cutaneous zygomycosis caused by Cunninghamella bertholletiae in a patient with chronic myelogenous leukemia in blast crisis. Am J Hematol. 2009;84:447–8.

    PubMed  Google Scholar 

  10. Bearer EA, Nelson PR, Chowers MY, Davis CE. Cutaneous zygomycosis caused by Saksenaea vasiformis in a diabetic patient. J Clin Microbiol. 1994;32:1823–4.

    CAS  PubMed  Google Scholar 

  11. Lye GR, Wood G, Nimmo G. Subcutaneous zygomycosis due to Saksenaea vasiformis: rapid isolate identification using a modified sporulation technique. Pathology. 1996;28:364–5.

    CAS  PubMed  Google Scholar 

  12. Pritchard RC, Muir DB, Archer KH, Beith JM. Subcutaneous zygomycosis due to Saksenaea vasiformis in an infant. Med J Australia. 1986;145:630–1.

    CAS  PubMed  Google Scholar 

  13. Gonis G, Starr M. Fatal rhinoorbital mucormycosis caused by Saksenaea vasiformis in an immunocompromised child. Pediatr Infect Dis J. 1997;16:714–6.

    CAS  PubMed  Google Scholar 

  14. Hay RJ, Campbell CK, Marshall WM, Rees BI, Pincott J. Disseminated zygomycosis (mucormycosis) caused by Saksenaea vasiformis. J Infect. 1983;7:162–5.

    CAS  PubMed  Google Scholar 

  15. Torell J, Cooper BH, Helgeson NG. Disseminated Saksenaea vasiformis infection. Am J Clin Pathol. 1981;76:116–21.

    CAS  PubMed  Google Scholar 

  16. Kemna ME, Neri RC, Ali R, Salkin IF. Cokeromyces recurvatus, a mucoraceous zygomycete rarely isolated in clinical laboratories. J Clin Microbiol. 1994;32:843–5.

    CAS  PubMed  Google Scholar 

  17. Kamalam A, Thambiah AS. Cutaneous infection by Syncephalastrum. Sabouraudia. 1980;18:19–20.

    CAS  PubMed  Google Scholar 

  18. Verweij PE, Voss A, Donnelly JP, de Pauw BE, Meis JF. Wooden sticks as the source of a pseudoepidemic of infection with Rhizopus microsporus var. rhizopodiformis among immunocompromised patients. J Clin Microbiol. 1997;35:2422–3.

    CAS  PubMed  Google Scholar 

  19. Al-Asiri RH, Van Dijken PJ, Mahmood MA, Al-Shahed MS, Rossi ML, Osoba AO. Isolated hepatic mucormycosis in an immunocompetent child. Am J Gastroenterol. 1996;91:606–7.

    CAS  PubMed  Google Scholar 

  20. Del Valle Zapico A, Rubio Suárez A, Mellado Encinas P, Morales Angulo C, Cabrera Pozuelo E. Mucormycosis of the sphenoid sinus in an otherwise healthy patient. Case report and literature review. J Laryngol Otol. 1996;110:471–3.

    PubMed  Google Scholar 

  21. Petrikkos G, Skiada A, Sambatakou H, et al. Mucormycosis: ten-year experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis. 2003;22:753–6.

    CAS  PubMed  Google Scholar 

  22. O’Connell MA, Pluss JL, Schkade P, Henry AR, Goodman DL. Rhizopus-induced hypersensitivity pneumonitis in a tractor driver. J Allergy Clin Immunol. 1995;95:779–80.

    PubMed  Google Scholar 

  23. Wimander K, Belin L. Recognition of allergic alveolitis in the trimming department of a Swedish sawmill. Eur J Respir Dis Suppl. 1980;107:163–7.

    CAS  PubMed  Google Scholar 

  24. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–17.

    PubMed  Google Scholar 

  25. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851–6.

    CAS  PubMed  Google Scholar 

  26. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24:307–12.

    CAS  PubMed  Google Scholar 

  27. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350:950–2.

    CAS  PubMed  Google Scholar 

  28. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis. 2004;17:517–25.

    CAS  PubMed  Google Scholar 

  29. Lueg EA, Ballagh RH, Forte V. Analysis of the recent cluster of invasive fungal sinusitis at the Toronto Hospital for Sick Children. J Otolaryngol. 1996;25:366–70.

    CAS  PubMed  Google Scholar 

  30. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest. 1984;74:150–60.

    CAS  PubMed  Google Scholar 

  31. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis. 2009;199:1399–406.

    CAS  PubMed  Google Scholar 

  32. Diamond RD, Krzesicki R, Epstein B, Jao W. Damage to hyphal forms of fungi by human leukocytes in vitro. A possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol. 1978;91:313–28.

    CAS  PubMed  Google Scholar 

  33. Marx RS, Forsyth KR, Hentz SK. Mucorales species activation of a serum leukotactic factor. Infect Immun. 1982;38:1217–22.

    CAS  PubMed  Google Scholar 

  34. Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser. 1989;47:243–71.

    CAS  PubMed  Google Scholar 

  35. Diamond RD, Haudenschild CC, Erickson NF. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun. 1982;38:292–7.

    CAS  PubMed  Google Scholar 

  36. Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun. 1982;38:1123–9.

    CAS  PubMed  Google Scholar 

  37. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes. 1982;31:1109–14.

    CAS  PubMed  Google Scholar 

  38. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993;91:1979–86.

    CAS  PubMed  Google Scholar 

  39. Howard DH. Acquisition, transport, and storage of iron by pathogenic fungi. Clin Microbiol Rev. 1999;12:394–404.

    CAS  PubMed  Google Scholar 

  40. de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol. 1994;47:1843–50.

    PubMed  Google Scholar 

  41. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 1994;45:667–71.

    CAS  PubMed  Google Scholar 

  42. Ibrahim AS, Spellberg B, Edwards Jr J. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008;21:620–5.

    CAS  PubMed  Google Scholar 

  43. Ibrahim AS, Edwards JE, Jr, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006;58:1070–3.

    CAS  PubMed  Google Scholar 

  44. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649–57.

    CAS  PubMed  Google Scholar 

  45. Stearman R, Yuan DS, Yamaguchi-Iwai Y, Klausner RD, Dancis A. A permease-oxidase complex involved in high-affinity iron uptake in yeast. Science. 1996;271:1552–7.

    CAS  PubMed  Google Scholar 

  46. Ibrahim AS, Gebermariam T, Lin L, Luo G, Husseiny MI, Skory CD, Fu Y, French SW, Edwards JE, Jr, Spellberg B. The high affinity iron permeasc is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol. 2010;77:587–604.

    Google Scholar 

  47. Santos R, Buisson N, Knight S, Dancis A, Camadro JM, Lesuisse E. Haemin uptake and use as an iron source by Candida albicans: role of CaHMX1-encoded haem oxygenase. Microbiology. 2003;149:579–88.

    CAS  PubMed  Google Scholar 

  48. Worsham PL, Goldman WE. Quantitative plating of Histoplasma capsulatum without addition of conditioned medium or siderophores. J Med Vet Mycol. 1988;26:137–43.

    CAS  PubMed  Google Scholar 

  49. Ma LJ, Ibrahim AS, Skory C, et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet. 2009;5:e1000549.

    PubMed  Google Scholar 

  50. Ibrahim AS, Edwards JE, Jr, Filler SG. Zygomycosis. In: Dismukes WE, Pappas PG, Sobel JD, editors. Clinical mycology. New York: Oxford University Press; 2003. p. 241–51.

    Google Scholar 

  51. Bouchara JP, Oumeziane NA, Lissitzky JC, Larcher G, Tronchin G, Chabasse D. Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. Eur J Cell Biol. 1996;70:76–83.

    CAS  PubMed  Google Scholar 

  52. Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE, Jr. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005;73:778–83.

    CAS  PubMed  Google Scholar 

  53. Wang M, Wey S, Zhang Y, Ye R, Lee AS. Role of the unfolded protein response regulator GRP78/BiP in development, cancer and neurological disorders. Antioxidants Redox Signal. 2009;11:2307–16.

    CAS  Google Scholar 

  54. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett. 2007;581:3641–51.

    CAS  PubMed  Google Scholar 

  55. Liu M, Spellberg B, Phan QT, Fu Y, Lec AS, Edwards JE Jr. Filler SG, Ibrahim AS. The endothelial cell receptor GRP78 is required for macormycosis pathogenesis in diabetic mice. J Clin Invest; 2010;120:1914–1924.

    Google Scholar 

  56. Jennessen J, Nielsen KF, Houbraken J, et al. Secondary metabolite and mycotoxin production by the Rhizopus microsporus group. J Agric Food Chem. 2005;53:1833–40.

    CAS  PubMed  Google Scholar 

  57. Partida-Martinez LP, Hertweck C. Pathogenic fungus harbours endosymbiotic bacteria for toxin production. Nature. 2005;437:884–8.

    CAS  PubMed  Google Scholar 

  58. Ibrahim AS, Gebremariam T, Liu M, et al. Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis. J Infect Dis. 2008;198:1083–90.

    CAS  PubMed  Google Scholar 

  59. Farley PC, Sullivan PA. The Rhizopus oryzae secreted aspartic proteinase gene family: an analysis of gene expression. Microbiology. 1998;144(Pt 8):2355–66.

    CAS  PubMed  Google Scholar 

  60. Anand VK, Alemar G, Griswold Jr JA. Intracranial complications of mucormycosis: an experimental model and clinical review. Laryngoscope. 1992;102:656–62.

    CAS  PubMed  Google Scholar 

  61. Pillsbury HC, Fischer ND. Rhinocerebral mucormycosis. Arch Otolaryngol. 1977;103:600–4.

    CAS  PubMed  Google Scholar 

  62. McNulty JS. Rhinocerebral mucormycosis: predisposing factors. Laryngoscope. 1982;92:1140–3.

    CAS  PubMed  Google Scholar 

  63. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope. 1997;107:855–62.

    CAS  PubMed  Google Scholar 

  64. Yanagisawa E, Friedman S, Kundargi RS, Smith HW. Rhinocerebral phycomycosis. Laryngoscope. 1977;87:1319–35.

    CAS  PubMed  Google Scholar 

  65. Abedi E, Sismanis A, Choi K, Pastore P. Twenty-five years’ experience treating cerebro-rhino-orbital mucormycosis. Laryngoscope. 1984;94:1060–2.

    CAS  PubMed  Google Scholar 

  66. Lowe Jr JT, Hudson WR. Rhincerebral phycomycosis and internal carotid artery thrombosis. Arch Otolaryngol. 1975;101:100–3.

    PubMed  Google Scholar 

  67. LeCompte PM, Miessner WA. Mucormycosis of the central nervous system associated with hemochromatosis. Am J Pathol. 1947;23:673–6.

    CAS  PubMed  Google Scholar 

  68. Bullock JD, Jampol LM, Fezza AJ. Two cases of orbital phycomycosis with recovery. Am J Ophthalmol. 1974;78:811–5.

    CAS  PubMed  Google Scholar 

  69. Parfrey NA. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine. 1986;65:113–23.

    CAS  PubMed  Google Scholar 

  70. Blitzer A, Lawson W, Meyers BR, Biller HF. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope. 1980;90:635–48.

    CAS  PubMed  Google Scholar 

  71. Morrison VA, McGlave PB. Mucormycosis in the BMT population. Bone Marrow Transplant. 1993;11:383–8.

    CAS  PubMed  Google Scholar 

  72. Rothstein RD, Simon GL. Subacute pulmonary mucormycosis. J Med Vet Mycol. 1986;24:391–4.

    CAS  PubMed  Google Scholar 

  73. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57:1044–50.

    CAS  PubMed  Google Scholar 

  74. Harada M, Manabe T, Yamashita K, Okamoto N. Pulmonary mucormycosis with fatal massive hemoptysis. Acta Pathol Jpn. 1992;42:49–55.

    CAS  PubMed  Google Scholar 

  75. Watts WJ. Bronchopleural fistula followed by massive fatal hemoptysis in a patient with pulmonary mucormycosis. A case report. Arch Intern Med. 1983;143:1029–30.

    CAS  PubMed  Google Scholar 

  76. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma. 2004;45:1351–60.

    CAS  PubMed  Google Scholar 

  77. Kerr OA, Bong C, Wallis C, Tidman MJ. Primary cutaneous mucormycosis masquerading as pyoderma gangrenosum. Br J Dermatol. 2004;150:1212–3.

    CAS  PubMed  Google Scholar 

  78. Gartenberg G, Bottone EJ, Keusch GT, Weitzman I. Hospital-acquired mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous tissue: epidemiology, mycology and treatment. N Engl J Med. 1978;299:1115–8.

    CAS  PubMed  Google Scholar 

  79. Mead JH, Lupton GP, Dillavou CL, Odom RB. Cutaneous Rhizopus infection. Occurrence as a postoperative complication associated with an elasticized adhesive dressing. J Am Med Assoc. 1979;242:272–4.

    CAS  Google Scholar 

  80. Ledgard JP, van Hal S, Greenwood JE. Primary cutaneous zygomycosis in a burns patient: a review. J Burn Care Res. 2008;29:286–90.

    PubMed  Google Scholar 

  81. Boyd AS, Wiser B, Sams HH, King LE. Gangrenous cutaneous mucormycosis in a child with a solid organ transplant: a case report and review of the literature. Pediatr Dermatol. 2003;20:411–5.

    PubMed  Google Scholar 

  82. Kordy FN, Al-Mohsen IZ, Hashem F, Almodovar E, Al Hajjar S, Walsh TJ. Successful treatment of a child with posttraumatic necrotizing fasciitis caused by Apophysomyces elegans: case report and review of literature. Pediatr Infect Dis J. 2004;23:877–9.

    PubMed  Google Scholar 

  83. Prasad RM, Bose SM, Vaiphei K, Verma GR. Post operative abdominal wall mucormycosis mimicking as bacterial necrotising fasciitis. J Postgrad Med. 2003;49:187–8.

    CAS  PubMed  Google Scholar 

  84. Amin SB, Ryan RM, Metlay LA, Watson WJ. Absidia corymbifera infections in neonates. Clin Infect Dis. 1998;26:990–2.

    CAS  PubMed  Google Scholar 

  85. Sharma MC, Gill SS, Kashyap S, et al. Gastrointestinal mucormycosis–an uncommon isolated mucormycosis. Indian J Gastroenterol. 1998;17:131–3.

    CAS  PubMed  Google Scholar 

  86. Straatsma BR, Zimmerman LE, Gass JDM. Phycomycosis: a clinicopathologic study of fifty-one cases. Lab Invest. 1962;11:963–85.

    CAS  PubMed  Google Scholar 

  87. Woods KF, Hanna BJ. Brain stem mucormycosis in a narcotic addict with eventual recovery. Am J Med. 1986;80:126–8.

    CAS  PubMed  Google Scholar 

  88. Virmani R, Connor DH, McAllister HA. Cardiac mucormycosis. A report of five patients and review of 14 previously reported cases. Am J Clin Pathol. 1982;78:42–7.

    CAS  PubMed  Google Scholar 

  89. Tuder RM. Myocardial infarct in disseminated mucormycosis: case report with special emphasis on the pathogenic mechanisms. Mycopathologia. 1985;89:81–8.

    CAS  PubMed  Google Scholar 

  90. Vesa J, Bielsa O, Arango O, Lladó C, Gelabert A. Massive renal infarction due to mucormycosis in an AIDS patient. Infection. 1992;20:234–6.

    CAS  PubMed  Google Scholar 

  91. Maliwan N, Reyes CV, Rippon JW. Osteomyelitis secondary to cutaneous mucormycosis. Report of a case and a review of the literature. Am J Dermatopathol. 1984;6:479–81.

    CAS  PubMed  Google Scholar 

  92. Pierce PF, Wood MB, Roberts GD, Fitzgerald Jr RH, Robertson C, Edson RS. Saksenaea vasiformis osteomyelitis. J Clin Microbiol. 1987;25:933–5.

    CAS  PubMed  Google Scholar 

  93. Leong ASY. Granulomatous mediastinitis due to Rhizopus species. Am J Clin Pathol. 1978;70:103–7.

    CAS  PubMed  Google Scholar 

  94. Connor BA, Anderson RJ, Smith JW. Mucor mediastinitis. Chest. 1979;75:524–6.

    Google Scholar 

  95. Andrews DR, Allan A, Larbalestier RI. Tracheal mucormycosis. Ann Thorac Surg. 1997;63:230–2.

    CAS  PubMed  Google Scholar 

  96. Helenglass G, Elliott JA, Lucie NP. An unusual presentation of opportunistic mucormycosis. Br Med J (Clin Res ed). 1981;282:108–9.

    CAS  Google Scholar 

  97. Ogunlana EO. Fungal air spora at Ibadan, Nigeria. Appl Microbiol. 1975;29:458–63.

    CAS  PubMed  Google Scholar 

  98. Mori T, Egashira M, Kawamata N, et al. Zygomycosis: two case reports and review of reported cases in the literature in Japan. Nippon Ishinkin Gakkai Zasshi. 2003;44:163–79.

    PubMed  Google Scholar 

  99. Tietz HJ, Brehmer D, Jänisch W, Martin H. Incidence of endomycoses in the autopsy material of the Berlin Charité Hospital. Mycoses. 1998;41 Suppl 2:81–5.

    PubMed  Google Scholar 

  100. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.

    CAS  PubMed  Google Scholar 

  101. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41:60–6.

    PubMed  Google Scholar 

  102. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis. 2008;46:1733–7.

    PubMed  Google Scholar 

  103. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503–9.

    PubMed  Google Scholar 

  104. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.

    PubMed  Google Scholar 

  105. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764–71.

    CAS  PubMed  Google Scholar 

  106. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383–96.

    CAS  PubMed  Google Scholar 

  107. Ibrahim AS, Avanessian V, Spellberg B, Edwards Jr JE. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother. 2003;47:3343–4.

    CAS  PubMed  Google Scholar 

  108. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182:274–82.

    CAS  PubMed  Google Scholar 

  109. Ibrahim AS, Gebremariam T, Husseiny MI, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother. 2008;52:1573–6.

    CAS  PubMed  Google Scholar 

  110. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46:1581–2.

    CAS  PubMed  Google Scholar 

  111. Blin N, Morineau N, Gaillard F, et al. Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin’s lymphoma. Leuk Lymphoma. 2004;45:2161–3.

    PubMed  Google Scholar 

  112. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743–6.

    PubMed  Google Scholar 

  113. Kobayashi K, Kami M, Murashige N, Kishi Y, Fujisaki G, Mitamura T. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica 2004;89:ECR42.

    Google Scholar 

  114. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–60.

    PubMed  Google Scholar 

  115. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis. 2005;40:770–1.

    PubMed  Google Scholar 

  116. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032–7.

    CAS  PubMed  Google Scholar 

  117. Lass-Florl C, Mayr A, Perkhofer S, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2008;52:3637–41.

    PubMed  Google Scholar 

  118. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol. 2008;12:1–7.

    Google Scholar 

  119. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50:658–66.

    CAS  PubMed  Google Scholar 

  120. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27:1627–36.

    CAS  PubMed  Google Scholar 

  121. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin. 2007;23:545–52.

    CAS  PubMed  Google Scholar 

  122. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51:812–8.

    CAS  PubMed  Google Scholar 

  123. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46:2310–2.

    CAS  PubMed  Google Scholar 

  124. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother. 2003;47:3647–50.

    CAS  PubMed  Google Scholar 

  125. Ibrahim AS, Gebremariam T, Schwartz JA, Edwards Jr JE, Spellberg B. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother. 2009;53:772–5.

    CAS  PubMed  Google Scholar 

  126. Rodriguez MM, Serena C, Marine M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine-disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52:3786–8.

    CAS  PubMed  Google Scholar 

  127. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:e61–5.

    PubMed  Google Scholar 

  128. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126–33.

    CAS  PubMed  Google Scholar 

  129. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41:3623–6.

    CAS  PubMed  Google Scholar 

  130. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003;20:121–36.

    PubMed  Google Scholar 

  131. Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1, 3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005;49:721–7.

    CAS  PubMed  Google Scholar 

  132. Spellberg B, Fu Y, Edwards Jr JE, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49:830–2.

    CAS  PubMed  Google Scholar 

  133. Ibrahim AS, Gebremariam T, Fu Y, Edwards Jr JE, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52:1556–8.

    CAS  PubMed  Google Scholar 

  134. Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-Mediated beta-Glucan Unmasking and Enhancement of Human Polymorphonuclear Neutrophil Activity against Aspergillus and Non-Aspergillus Hyphae. J Infect Dis. 2008;198:186–92.

    CAS  PubMed  Google Scholar 

  135. Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol. 2005;18:289–98.

    CAS  PubMed  Google Scholar 

  136. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649–57.

    CAS  PubMed  Google Scholar 

  137. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–80.

    CAS  PubMed  Google Scholar 

  138. Miyazawa K, Ohyashiki K, Urabe A, et al. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. Int J Hematol. 2008;88:73–81.

    CAS  PubMed  Google Scholar 

  139. Reed C, Ibrahim A, Edwards Jr JE, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006;50:3968–9.

    PubMed  Google Scholar 

  140. Spellberg B, Andes D, Perez M, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53:3122–5.

    CAS  PubMed  Google Scholar 

  141. Soummer A, Mathonnet A, Scatton O, et al. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob Agents Chemother. 2008;52:1585–6.

    CAS  PubMed  Google Scholar 

  142. Couch L, Theilen F, Mader JT. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg. 1988;114:791–4.

    CAS  PubMed  Google Scholar 

  143. Robb SM. Reactions of fungi to exposure to 10 atmospheres pressure of oxygen. J Gen Microbiol. 1966;45:17–29.

    Google Scholar 

  144. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon- gamma and Granulocyte-Macrophage Colony-Stimulating Factor Augment the Activity of Polymorphonuclear Leukocytes against Medically Important Zygomycetes. J Infect Dis. 2005;191:1180–7.

    CAS  PubMed  Google Scholar 

  145. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004;23:769–73.

    PubMed  Google Scholar 

  146. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis. 1997;24:192–6.

    CAS  PubMed  Google Scholar 

  147. Kullberg BJ, Anaissie EJ. Cytokines as therapy for opportunistic fungal infections. Res Immunol. 1998;149:478–88. discussion 515.

    CAS  PubMed  Google Scholar 

  148. Ma B, Seymour JF, Januszewicz H, Slavin MA. Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF. Leuk Lymphoma. 2001;42:1393–9.

    CAS  PubMed  Google Scholar 

  149. Mastroianni A. Paranasal sinus mucormycosis in an immunocompetent host: efficacy and safety of combination therapy with Liposomal Amphotericin B and adjuvant rHuGM-CSF. Infez Med. 2004;12:278–83.

    PubMed  Google Scholar 

  150. Grigull L, Beilken A, Schmid H, et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer. 2006;14:783–6.

    PubMed  Google Scholar 

  151. Slavin MA, Kannan K, Buchanan MR, Sasadeusz J, Roberts AW. Successful allogeneic stem cell transplant after invasive pulmonary zygomycosis. Leuk Lymphoma. 2002;43:437–9.

    CAS  PubMed  Google Scholar 

  152. Thakar A, Baruah P, Kumar S, Sharma MC. Rhinophycomycosis. J Laryngol Otol. 2001;115:493–6.

    CAS  PubMed  Google Scholar 

  153. Yang X, Li Y, Zhou X, et al. Rhinofacial conidiobolomycosis caused by Conidiobolus coronatus in a Chinese rice farmer. Mycoses. 2010;53(4):369–73.

    PubMed  Google Scholar 

  154. Gugnani HC. Entomophthoromycosis due to Conidiobolus. Eur J Epidemiol. 1992;8:391–6.

    CAS  PubMed  Google Scholar 

  155. Martinson FD. Chronic phycomycosis of the upper respiratory tract. Rhinophycomycosis entomophthorae. Am J Trop Med Hyg. 1971;20:449–55.

    CAS  PubMed  Google Scholar 

  156. Dworzack DL, Pollock AS, Hodges GR, Barnes WG, Ajello L, Padhye A. Zygomycosis of the maxillary sinus and palate caused by Basidiobolus haptosporus. Arch Intern Med. 1978;138:1274–6.

    CAS  PubMed  Google Scholar 

  157. Walsh TJ, Renshaw G, Andrews J, et al. Invasive zygomycosis due to Conidiobolus incongruus. Clin Infect Dis. 1994;19:423–30.

    CAS  PubMed  Google Scholar 

  158. Tan DC, Hsu LY, Koh LP, Goh YT, Koh M. Severe conidiobolomycosis complicating induction chemotherapy in a patient with acute lymphoblastic leukaemia. Br J Haematol. 2005;129:447.

    PubMed  Google Scholar 

  159. Okafor JI, Testrake D, Mushinsky HR, Yangco BG. A Basidiobolus sp. and its association with reptiles and amphibians in southern Florida. Sabouraudia. 1984;22:47–51.

    CAS  PubMed  Google Scholar 

  160. Rippon JW. Medical mycology. 2nd ed. Philadelphia: The W.B. Saunders Company; 1982. p. 303–14.

    Google Scholar 

  161. Dreschler C. Two new species of Conidiobolus found in the plant detritus. Am J Bot. 1960;47:368–77.

    Google Scholar 

  162. Costa AR, Porto E, Pegas JR, et al. Rhinofacial zygomycosis caused by Conidiobolus coronatus. A case report. Mycopathologia. 1991;115:1–8.

    CAS  PubMed  Google Scholar 

  163. Cameroon HM. Entomophthoromycosis. In: Mahgoub ES, editor. Tropical mycoses. Beerse: Janssen Research Council; 1990. p. 186–98.

    Google Scholar 

  164. Dreschler C. Supplementary development stages of Basidiobolus ranarum and Basidiobolus haptosporus. Mycologia. 1956;48:655–77.

    Google Scholar 

  165. Goodman NL, Rinaldi MG. Agents of zygomycosis. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ, editors. Manual of clinical microbiology. 5th ed. Washington: ASM Press; 1991. p. 674–92.

    Google Scholar 

  166. Bittencourt AL, Arruda SM, de Andrade JA, Carvalho EM. Basidiobolomycosis: a case report. Pediatr Dermatol. 1991;8:325–8.

    CAS  PubMed  Google Scholar 

  167. Chandler FW, Watts JC. Pathologic diagnosis of fungal infections. Chicago: ASCP Press; 1987. p. 85–95.

    Google Scholar 

  168. Kamalam A, Thambiah AS. Muscle invasion by Basidiobolus haptosporus. Sabouraudia. 1984;22:273–7.

    CAS  PubMed  Google Scholar 

  169. van den Berk GE, Noorduyn LA, van Ketel RJ, van Leeuwen J, Bemelman WA, Prins JM. A fatal pseudo-tumour: disseminated basidiobolomycosis. BMC Infect Dis. 2006;6:140.

    PubMed  Google Scholar 

  170. Pasha TM, Leighton JA, Smilack JD, Heppell J, Colby TV, Kaufman L. Basidiobolomycosis: an unusual fungal infection mimicking inflammatory bowel disease. Gastroenterology. 1997;112:250–4.

    CAS  PubMed  Google Scholar 

  171. Al Jarie A, Al-Mohsen I, Al Jumaah S, et al. Pediatric gastrointestinal basidiobolomycosis. Pediatr Infect Dis J. 2003;22:1007–14.

    PubMed  Google Scholar 

  172. Hussein MR, Musalam AO, Assiry MH, Eid RA, El Motawa AM, Gamel AM. Histological and ultrastructural features of gastrointestinal basidiobolomycosis. Mycol Res. 2007;111:926–30.

    PubMed  Google Scholar 

  173. Bigliazzi C, Poletti V, Dell’Amore D, Saragoni L, Colby TV. Disseminated basidiobolomycosis in an immunocompetent woman. J Clin Microbiol. 2004;42:1367–9.

    PubMed  Google Scholar 

  174. Singh R, Xess I, Ramavat AS, Arora R. Basidiobolomycosis: a rare case report. Indian J Med Microbiol. 2008;26:265–7.

    CAS  PubMed  Google Scholar 

  175. Onuigbo WI, Gugnani HC, Okafor BC, Misch KA. Nasal entomophthorosis in an Igbo from Nigeria. J Laryngol Otol. 1975;89:657–61.

    CAS  PubMed  Google Scholar 

  176. Ravisse P, Destombes P, Le Gonidec G. 10 new clinical cases of mycoses caused by Entomophorales in Cameroon. Bull Soc Pathol Exot Filiales. 1976;69:33–40.

    CAS  PubMed  Google Scholar 

  177. Bittencourt AL, Serra G, Sadigursky M, Araujo MG, Campos MC, Sampaio LC. Subcutaneous zygomycosis caused by Basidiobolus haptosporus: presentation of a case mimicking Burkitt’s lymphoma. Am J Trop Med Hyg. 1982;31:370–3.

    CAS  PubMed  Google Scholar 

  178. Okafor BC, Gugnani HC, Jacob A. Nasal entomophthorosis with laryngeal involvement. Mykosen. 1983;26:471–7.

    CAS  PubMed  Google Scholar 

  179. Drouhet E, Dupont B. Laboratory and clinical assessment of ketoconazole in deep-seated mycoses. Am J Med. 1983;74:30–47.

    CAS  PubMed  Google Scholar 

  180. Restrepo A. Treatment of tropical mycoses. J Am Acad Dermatol. 1994;31:S91–102.

    CAS  PubMed  Google Scholar 

  181. Barro-Traore F, Ouedraogo D, Konsem T, et al. Conidiobolomycosis, a rare fungal tumor: a case report in Ouagadougou, Burkina Faso. Bull Soc Pathol Exot. 2008;101:14–6.

    CAS  PubMed  Google Scholar 

  182. Mathew R, Kumaravel S, Kuruvilla S, et al. Successful treatment of extensive basidiobolomycosis with oral itraconazole in a child. Int J Dermatol. 2005;44:572–5.

    PubMed  Google Scholar 

  183. Yangco BG, Okafor JI, TeStrake D. In vitro susceptibilities of human and wild-type isolates of Basidiobolus and Conidiobolus species. Antimicrob Agents Chemother. 1984;25:413–6.

    CAS  PubMed  Google Scholar 

  184. Mukhopadhyay D, Ghosh LM, Thammayya A, Sanyal M. Entomophthoromycosis caused by Conidiobolus coronatus: clinicomycological study of a case. Auris Nasus Larynx. 1995;22:139–42.

    CAS  PubMed  Google Scholar 

  185. Foss NT, Rocha MR, Lima VT, Velludo MA, Roselino AM. Entomophthoramycosis: therapeutic success by using amphotericin B and terbinafine. Dermatology. 1996;193:258–60.

    CAS  PubMed  Google Scholar 

  186. Fischer N, Ruef C, Ebnother C, Bachli EB. Rhinofacial Conidiobolus coronatus infection presenting with nasal enlargement. Infection. 2008;36:594–6.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Harbor-UCLA Research and Education Institute, Torrance, CA, USA

    Ashraf S. Ibrahim

Authors
  1. Ashraf S. Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John E. Edwards Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Scott G. Filler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brad Spellberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashraf S. Ibrahim .

Editor information

Editors and Affiliations

  1. Veterans Affairs Ann Arbor Healthcare, Professor of Internal Medicine, University of Michigan Medical School, 2215 Fuller Road, Ann Arbor, 48105, Michigan, USA

    Carol A. Kauffman

  2. Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Blvd., Birmingham, 35294, Alabama, USA

    Peter G. Pappas

  3. Division of Infectious Diseases, Wayne State University School of Medicin, 3990 John R Street, Detroit, 48201, Michigan, USA

    Jack D. Sobel

  4. School of Medicine, Professor Emeritus of Medicine, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, 35294, Alabama, USA

    William E. Dismukes

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ibrahim, A.S., Edwards, J.E., Filler, S.G., Spellberg, B. (2011). Mucormycosis and Entomophthoramycosis (Zygomycosis). In: Kauffman, C., Pappas, P., Sobel, J., Dismukes, W. (eds) Essentials of Clinical Mycology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6640-7_15

Download citation

Publish with us

Policies and ethics

Search

Navigation